Related Experiment Video
Updated: Jul 14, 2026
Detection of Rare Mutations in CtDNA Using Next Generation Sequencing
Published on: August 24, 2017
Current Evidence for Circulating Tumor DNA in Sarcoma: Challenges and Opportunities for Clinical Application
Kristin E Goodsell1, Jason A Carter1, Hannah R Abrams2,3
1Department of Surgery, University of Washington, Seattle, Washington, USA.
Abstract:
Sarcomas represent a diverse group of mesenchymal tumors with high rates of recurrence after resection. While recent technical advances have enabled the detection of rare circulating tumor DNA (ctDNA) in other malignancies, the complexity and heterogeneity of sarcoma genomics have historically limited ctDNA in these cancers. This narrative review highlights the rapidly evolving evidence supporting potential clinical applications of ctDNA in common sarcoma subtypes including gastrointestinal stromal tumor, leiomyosarcoma, rhabdomyosarcoma, osteosarcoma, and Ewing sarcoma.
Insights
Circulating tumor DNA (ctDNA) shows promise for monitoring sarcoma recurrence. Despite genomic complexity, ctDNA detection is improving for sarcoma subtypes, offering new clinical applications.
Area of Science:
- Oncology
- Genomics
- Molecular Diagnostics
Background:
- Sarcomas are diverse mesenchymal tumors with frequent recurrence post-resection.
- Genomic complexity and heterogeneity historically hindered circulating tumor DNA (ctDNA) detection in sarcomas.
- Advances in molecular techniques are improving ctDNA detectability.
Purpose of the Study:
- To review the evolving evidence for ctDNA applications in sarcoma.
- To highlight potential clinical uses of ctDNA across common sarcoma subtypes.
Main Methods:
- Narrative review of current literature.
- Focus on ctDNA detection and its clinical relevance in sarcoma.
Main Results:
- Emerging evidence supports ctDNA's role in managing sarcomas.
- Potential applications include early detection, monitoring treatment response, and detecting minimal residual disease.
- Specific sarcoma subtypes discussed include GIST, leiomyosarcoma, rhabdomyosarcoma, osteosarcoma, and Ewing sarcoma.
Conclusions:
- ctDNA is a rapidly advancing field with significant potential in sarcoma management.
- Further research is needed to fully integrate ctDNA into clinical practice for sarcoma patients.
